Experimental Therapeutics (ET)

17.0摘要：实验治疗计划 UMGCC的实验治疗(ET)计划的首要目标是开发和测试新的 基于创新的临床前研究的实体肿瘤和血液系统恶性肿瘤的治疗。这个 重点是将ET成员的基础和临床前发现带到早期临床测试和 此外，还为其他项目的研究人员提供平台，让他们在临床环境中研究他们的发现。至 为了实现这一使命，该方案侧重于三个具体主题和相关目标：主题1：分子 靶点-基于新的分子靶点开发和测试新的癌症疗法；主题2：治疗 交付-开发和测试癌症治疗和新区域治疗的新配方和交付策略 治疗；主题3：辐射--开发和测试利用电离和非电离的新战略 用于癌症综合管理中的辐射敏感化和防护。 ET计划有60名成员，代表16个学术部门和5所学校/学院 马里兰大学。该计划的成员进行癌症研究，获得1010万美元 年度资金总额，包括来自NCI的230万美元和来自其他同行审查来源的610万美元。在……里面 此外，人权委员会计划成员每年从非同行审查的资金来源获得170万美元。 在2010年1月至2014年12月期间，ET成员撰写了767份与癌症相关的出版物，其中 24%来自方案内协作，20%来自方案间协作。七十岁- 1%的出版物代表与外部调查人员的合作。ET的研究努力 BSS、FCS、GSS、ISS、PBSS和TLSS的广泛使用为教师提供了支持。

17.0 Abstract: Experimental Therapeutics Program The overarching goal of the Experimental Therapeutics (ET) Program of UMGCC is to develop and test new therapies for solid tumors and hematologic malignancies based on innovative preclinical research. The emphasis is on bringing basic and preclinical discoveries from ET members to early-stage clinical testing and also on providing platforms for investigators in other programs to study their findings in the clinical setting. To achieve this mission, the program focuses on three specific themes and related aims: Theme 1: Molecular targets—develop and test new cancer therapies based on novel molecular targets; Theme 2: Treatment delivery—develop and test novel formulations and delivery strategies for cancer treatments and new regional therapies; and Theme 3: Radiation—develop and test novel strategies for utilizing ionizing and nonionizing radiation and for radiation sensitization and protection in the multimodality management of cancers. The ET Program has 60 members representing 16 academic departments and 5 schools/colleges of the University of Maryland. Members of the program conduct cancer-focused research that receives $10.1 million total annual funding, including $2.3 million from NCI and $6.1 million from other peer-reviewed sources. In addition, HRC Program members receive $1.7 million annually from non-peer-reviewed funding sources. Between January 2010 and December 2014, ET members authored 767 cancer-related publications, of which 24 percent resulted from intraprogrammatic and 20 percent from interprogrammatic collaborations. Seventy- one percent of the publications represent collaborations with external investigators. Research efforts of ET faculty are supported by extensive use of the BSS, FCSS, GSS, ISS, PBSS, and TLSS.